Phase 3 (FDA rejection Aug 2024, resubmission pending)
MDMA Therapy
MDMA-assisted therapy is pursuing FDA approval for PTSD treatment. After a Phase 3 FDA rejection in August 2024, sponsors are preparing a resubmission with additional safety data.
50Clinical Trials
1Companies
0Legal States
FDA StatusPhase 3 (FDA rejection Aug 2024, resubmission pending)
Legal PathwayFDA approval pathway (federal)
Also Known Asecstasy, molly, midomafetamine
Legal Status by State
View full legal tracker →Legal
Decriminalized
Pending
No Legislation
Clinical Trials
12 trials currently recruiting
Phase 120
Phase 216
Phase 32
Completed·Phase 2·MDMA
MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD
VA Loma Linda Health Care System
Post Traumatic Stress DisorderCombat Stress Disorders
Completed·N/A·Other
Patient Doctor Lies
University of Utah
Patient LyingPrivacy StatementsRisk Statements+2 more
Not Yet Recruiting·Phase 2·MDMA
MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers
Nautilus Sanctuary
Post-Traumatic Stress DisorderAdjustment Disorders
Completed·Phase 2·MDMA
Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
Lykos Therapeutics
Social Anxiety in Autistic Adults
Recruiting·Early Phase 1·MDMA
MDMA-Assisted Therapy for Pathological Narcissism
University of Washington
Narcissism
Completed·N/A·Other
Characterization of the Prosocial and Prosexual Effects of GHB
University of Zurich
Depressive Disorder, MajorBipolar DisorderAutistic Disorder
Companies & Research
Organizations developing MDMA-based therapies